Cranberry does cut recurrent UTIs — in the people it helps, and not the ones it doesn't
A Cochrane review of 50 trials found cranberry products lower UTI risk in women with recurrent infections and in children, but no benefit in the elderly, in pregnancy, or in bladder-emptying problems.
Cranberry for urinary tract infections is neither the folk cure its defenders claim nor the placebo its critics dismiss — it depends entirely on who is taking it. The most current Cochrane review, pooling 50 trials and 8,857 participants, found that cranberry products reduce the risk of symptomatic, culture-confirmed UTIs overall, and specifically in women with recurrent infections and in children [s1]. In the same review, cranberry did nothing measurable for elderly residents of care homes, pregnant women, or people with incomplete bladder emptying [s1].
That split is the whole story, and it is why blanket statements in either direction are wrong.
What the pooled trials show
The 2023 Cochrane update is the largest synthesis of the question, with 26 new studies added since the prior version [s1]. Across the 6,211 participants in trials that could be combined, cranberry products reduced the risk of UTIs, with a risk ratio of 0.70 (95% CI 0.58 to 0.84) — about a 30% relative reduction — rated moderate-certainty evidence [s1].
When the reviewers split trials by who was taking cranberry, the benefit concentrated in specific groups. In women with recurrent UTIs, the risk ratio was 0.74 (95% CI 0.55 to 0.99) across 8 studies and 1,555 participants [s1]. In children it was 0.46, and in people made susceptible to UTIs by a medical intervention, 0.47 [s1]. These are the populations where cranberry has a real, if moderate, effect.
Where it does nothing
The review is equally clear about who is not helped, and this is the half usually left out. In elderly institutionalised men and women, the risk ratio was 0.93 (95% CI 0.67 to 1.30) — no benefit [s1]. In pregnant women it was 1.06 (95% CI 0.75 to 1.50), and in adults with neuromuscular bladder dysfunction and incomplete bladder emptying, 0.97 (95% CI 0.78 to 1.19) — no benefit in either [s1]. All three of those findings were rated moderate or low certainty, but the direction is unmistakable: the confidence intervals sit squarely across "no effect" [s1].
It is not a substitute for antibiotics
One comparison in the review addresses a question people rarely ask out loud: could cranberry replace antibiotics for prevention? The pooled data say the two performed similarly — cranberry versus antibiotics gave a risk ratio of 1.03 (95% CI 0.80 to 1.33) for culture-confirmed UTIs, meaning little or no difference [s1]. That is a narrower claim than "as good as antibiotics"; it rests on only two small studies and does not establish equivalence [s1]. It is best read as a reason cranberry is a reasonable option to try in the groups it helps, not evidence to abandon prescribed prophylaxis.
The professional guideline context reinforces the modest role. The AUA/CUA/SUFU guideline on recurrent uncomplicated UTIs in women exists precisely to reduce inappropriate antibiotic use and antibiotic resistance, and to lay out both antibiotic and non-antibiotic prevention strategies — the category cranberry falls into [s2]. Cranberry sits among the low-risk options a clinician may offer, not a front-line treatment for an active infection [s2].
The dose question, unresolved
For anyone reaching for a specific product, the review offers an uncomfortable finding: it could not identify a dose that works better. There was "no clear relationship between compliance with therapy and the risk for repeat UTIs," and no difference in UTI risk between low, moderate and high doses of proanthocyanidins, the active compounds in cranberry [s1]. Whether juice or tablets work better was rated very low certainty [s1]. Side effects were mild — the rate of gastrointestinal upset was not clearly different from placebo (risk ratio 1.33, 95% CI 1.00 to 1.77) [s1].
The bottom line the evidence supports is specific: cranberry products modestly reduce recurrent, culture-confirmed UTIs in women prone to them and in children, do not help several other groups, are not a treatment for an infection already present, and have no established best dose [s1] [s2]. That is more useful than either the enthusiasm or the dismissal that usually surrounds the question.
This article is informational and is not medical advice. A suspected urinary tract infection should be assessed by a clinician, and recurrent infections warrant a proper evaluation.
Sources
- Cranberries for preventing urinary tract infections — Cochrane Database of Systematic Reviews, 2023-11-10
- Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline — The Journal of Urology, 2019-05-01
Sources
- Cranberries for preventing urinary tract infections — Cochrane Database of Systematic Reviews , November 10, 2023
- Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline — The Journal of Urology , May 1, 2019
More on
What actually works for period pain: strong evidence for NSAIDs, weaker for exercise
Cochrane reviews rate anti-inflammatory painkillers a very effective treatment for menstrual cramps, roughly doubling the odds of good pain relief. Exercise helps too, but on lower-quality evidence.
Do pelvic floor exercises work? For stress incontinence, the evidence is strong
A Cochrane review found women doing pelvic floor muscle training were eight times more likely to report their stress incontinence cured than untreated women — with the strongest evidence for that one condition.
For recurrent UTIs, a non-antibiotic pill matched daily antibiotics in a trial
In the 240-woman ALTAR trial, methenamine hippurate was non-inferior to standard low-dose antibiotic prophylaxis over a year. Most other non-antibiotic prevention strategies still rest on weak evidence.
Supplements for depression: big effect sizes the authors call unrealistic
A network meta-analysis of 163 trials found EPA, vitamin D and a St John's wort extract beat placebo by margins so large the researchers treat them as a warning about the evidence, not a green light.